
From: Michael Kaplan ([REDACTED]) <[REDACTED]>
Sent: Wednesday, October 3, 2018 3:25 PM
To: jeevacation@gmail.com
Subject: Announcing MRA's Next Chief Science Officer

Dear Jeffrey,

<=:p>

As a valued member of the Melanoma Research Alliance family and a generous contributor to our work, I am writing to let you know about some exciting changes here at MRA that will be announced publicly tomorrow.

<=:p>

It is with great enthusiasm that I share with you that Dr. Marc Hurlbert, Ph.D., will join the MRA team on November 1st as our next Chief Science Officer (CSO). Dr. Hurlbert comes to MRA with more than 15 years of experience leading programs to advance medical research and improve patient outcomes. We are confident he will be a tremendous asset to MRA and the fight against melanoma.

&n=sp;

A formal announcement of Dr. Hurlbert's appointment will be made tomorrow. An embargoed copy of the press statement is available <<https://www.curemelanoma.org/assets/Uploads/MRA-Hurlbert-V3.pdf>> .

</=:p>

I would also like to take this opportunity to thank Dr. Louise Perkins for her more than five years of service as MRA's Chief Science Officer. While excited for her retirement, Louise has graciously agreed to continue with MRA in an advisory role through our 2019 grant review and Scientific Retreat. MRA would not be the organization it is without Dr. Perkins. We are eternally grateful for her leadership, dedication and keen scientific insight.

<=:p>

Please join me in wishing Louise a joyous retirement and in welcoming Marc to the MRA family.

&n=sp;

&n=sp;

Michael Kaplan<=o:p>

President & CEO<=o:p>

(202) 3-6-8939 P | [REDACTED] C

1101 New York Ave., NW, Ste. 620

Washington, DC 2000=

&=bsp;

www.curemelanoma.org <<http://www.curemelanoma.org>>

&n=sp;